CADTH Canadian drug expert committee recommendation: Telotristat ethyl (Xermelo -- Ipsen Biopharmaceuticals Canada Inc) indication : for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone

The CADTH Canadian Drug Expert Committee (CDEC) recommends that telotristat ethyl not be reimbursed for the treatment of refractory carcinoid syndrome diarrhea, in combination SSA therapy, in patients inadequately controlled by SSA therapy alone. Telotristat failed to improve symptoms of importance...

Full description

Bibliographic Details

Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 2019, 2019
Edition:	Version: Final
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Canada Diarrhea / Drug Therapy Cost-benefit Analysis Antidiarrheals / Therapeutic Use Tryptophan Hydroxylase / Antagonists & Inhibitors Diarrhea / Etiology Malignant Carcinoid Syndrome / Complications
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK546257
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa